Biocure Technology, Inc. engages in the development and commercialization of biosimilar products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2008-03-27. The firm specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.
Follow-Up Questions
Who is the CEO of Biocure Technology Inc?
Mr. Yee Sing Cheng is the Chief Executive Officer of Biocure Technology Inc, joining the firm since 2023.
What is the price performance of BICTF stock?
The current price of BICTF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Biocure Technology Inc?
Biocure Technology Inc belongs to Metals & Mining industry and the sector is Materials
